FIGHT-202 (pemigatinib)
In previously treated advanced cholangiocarcinoma with FGFR2 fusions or rearrangements, what activity does pemigatinib show?
Trial design and population
Key results
In the FGFR2 fusion/rearrangement cohort, final-analysis ORR was 37.0% (95% CI 27.9–46.9), median duration of response 9.1 months, median PFS 7.0 months and median OS 17.5 months after median follow-up of 45.4 months.
Source-reported outcome visualization
Objective response rate · Best overall response
Bars display source-reported values for the named endpoint; where the endpoint is a median, bars compare medians and do not represent probabilities. No unreported rates are inferred.
Absolute Effect
Single-arm response rate; no comparator-based absolute benefit or NNT can be calculated.
NNT: Not applicable — single-arm study. No NNT is derived from median survival/PFS differences.
NNH / harm: Common treatment-emergent events included hyperphosphatemia (58.5%), alopecia (49.7%) and diarrhoea (47.6%); monitor phosphate, ocular toxicity and nail/skin effects.
NNT/NNH are only displayed where the endpoint and time horizon support a defensible absolute-risk calculation. Otherwise, the source-reported outcome is visualized.
Safety and treatment burden
Common treatment-emergent events included hyperphosphatemia (58.5%), alopecia (49.7%) and diarrhoea (47.6%); monitor phosphate, ocular toxicity and nail/skin effects.
Follow-up, maturity and limitations
This is not an adjuvant trial. FIGHT-202 studied previously treated advanced/metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements. Single-arm design limits comparative claims.
Clinical interpretation
Current-practice context · reviewed 20 October 2026
This page separates original trial findings from contemporary treatment context. Confirm current disease-specific guidelines, local regulatory status, biomarker requirements, prior treatment exposure and patient-specific contraindications before applying the evidence. Historical comparators may no longer represent current standard practice; subgroup findings and immature endpoints should not be generalized.